InsuranceTom said:It helps to ask what evidence would change your mind before you look at any.
I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.
One concrete data point for the thread. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.
Dr.SurgeonPGH said:I would rather people stopped quoting the 24% as if it were a licensed outcome.
There is a second half to this that has not been said yet. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemA narrower follow-up, since the general answer is now clear:
What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?
OP back with an update, since a thread like this is useless without one.
Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.